华东医药：2025年第一季度报告（英文版）

Huadong Medicine Co., Ltd.First Quarterly Report 2025 The Company and all members of the Board ofDirectors hereby guarantee that the information presented inthis report is authentic, accurate, complete, and free of any false records, misleading statements or materialomissions. Important Declaration: 1. The Board of Directors, Board of Supervisors,directors, supervisors and senior management of Huadong Medicine Co., Ltd.(hereinafter referred to as the“Company”)hereby guarantee that the information presented in this report is authentic, accurate, complete,and free of any false records, misleadingstatements or material omissions, and shall undertake individual and joint legal liabilities. 2. The Company’s legal representative, the officer in charge of accounting, and the head of accounting department (accounting manager)hereby declare that the financial information in this quarterly report is authentic, accurate, and complete. 3. Has the First Quarterly Report been audited? □YesNo According to“Stock Listing Rules of the Shenzhen Stock Exchange”,if listed companies have both Chinese andotherlanguage version of public notice, they should ensure the content of both versions are the same. In the caseof discrepancy, the original version in Chinese shall prevail. I. Key Financial Data (I) Key accounting data and financial indicators Whether the Company needs to perform a retroactive adjustment or restatement of previous accounting data□YesNo The Company’s total share capital as of the trading day prior to disclosure: (II) Items and amounts of non-recurring gains/losses Applicable □ N/A Unit: yuan There are no other items of gains/losses meeting the definition of non-recurring gains/losses. No item listedas a non-recurring gain/loss in theInterpretative Announcement No. 1 on Information Disclosure Criteria for PublicCompanies-Non-Recurring Gains/Lossesis recognized as a recurring gain/loss. (III) Details and reasons for changes in key accounting dataand financial indicators Applicable □ N/A Unit: ten thousand yuan II. Shareholder Information (I) Total number of common shareholders, number of preferred shareholders with restored voting rights, andshareholdings of the top10 shareholders Unit: share Participation of shareholders with a shareholding ratio of over 5%, the top 10 shareholders, and the top 10 shareholders holding tradableshares without trading restriction conditions in lending through conversions □ApplicableN/A Change in the top 10 shareholders or the top 10 common shareholders without trading restrictions compared with the end of thepreviousperiod due to shares lent/returned through conversions □ApplicableN/A (II) Total number of preferred shareholders of the Company and shareholdings of the top 10 shareholders □ApplicableN/A III. Other Important Matters Applicable □ N/A (I) Overview of the Company’s overall operations in the reporting period During the reporting period, the Company remained closely aligned with its overarchingstrategic blueprint and annual operational objectives. Guided by the principles of“reinvigorating entrepreneurialspirit,deepening reforms,strengthening organizational systems,and seizingdevelopmental opportunities,”the Company maintained a zero-based mindset and a relentless pursuitof excellence, vigorously advancing the effective implementation of various management initiatives. During the reporting period, the Company achieved an operating revenue of 10.736 billion yuan,up 3.12% year on year and up 2.95% compared with that in Q4 2024. The net profit attributable toshareholders of listed companies reached 915 million yuan, marking a 6.06% year-on-year increase.The net profit attributable to shareholders of listed companies after deducting non-recurringgains/losses stood at 897 million yuan, reaching a historic high with a 7.04% year-on-year increaseand a 3.16% quarter-on-quarter increase from that in Q4 2024.After deducting the profits and lossesof participating and holding R&D institutions, the net profit attributable to shareholders of listedcompanies after deducting non-recurring gains/losses during the reporting period amounted to 982million yuan, reflecting a 17.15% growth compared withthe Company’s net profit attributable toshareholders oflisted companiesafter deducting non-recurring gains/lossesin Q1 2024. During the reporting period, the Company’s core subsidiary Zhongmei Huadong witnessedsteady growth as a whole and achieved an operating revenue (including CSO business) of 3.621billion yuan, up 6.52% year on year, and the consolidated net profit attributable to the parent companyof 843 million yuan, up 12.20% year on year.During the reporting period, the Company’s innovativemedicines saw robust momentum in sales, driving sustained growth in the pharmaceutical industry.Leveragingits differentiated clinical value,the CAR-T Zevorcabtagene Autoleucel Injection(Saikaize®) has rapidly penetrated core treatment centers throughout China. W